Coronary heart disease in women: Triglycerides and lipoprotein biology

Journal of Gender-Specific Medicine

Volumn 5, Issue 5, 2002, Pages 27-33

  Dayspring, Thomas D ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NICOTINIC ACID; NORETHISTERONE ACETATE; NORGESTIMATE; PLACEBO; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ARTERY THROMBOSIS; CLINICAL TRIAL; DISEASE ASSOCIATION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MENOPAUSE; PATHOGENESIS; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRIGLYCERIDES;

EID: 0036768002     PISSN: 15237036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Mosca L, Grundy S, Judelson D, et al. AHA/ACC Scientific Statement: Consensus Panel Statement: Guide to Preventive Cardiology for Women. J Am Coll Cardiol 1999;33:1751-1755.
2. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
3. Executive Summary of the Third Report o the National Cholesterol Education Panel Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486-2497.
4. Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. HERS Research Group. JAMA 1998;280:605-613.
6. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease after menopause. JAMA 2000;283:1845-1852.
7. Clarke S, Kelleher J, Lloyd-Jones H, et al. Transdermal hormone replacement therapy for the secondary prevention of coronary artery disease in postmenopausal women [abstract]. Eur Heart J 2000;21:212.
8. Hsia J, Simon J, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: The HERS. Circulation 2000;102:2228-2232.
9. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: HERS. Circulation 2001;103:638-642.
10. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-1249.
11. Schulman SP, Thiemann DR, Ouyanq S, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2002;39:231-237.
12. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;289:321-333.
13. Lenfant C. Preliminary Trends in the Women's Health Initiative. Bethesda, MD: National Heart Lung and Blood Institute. April 3, 2000 press release.
14. Rossouw JE. Early risk of cardiovascular events after commencing hormone replacement therapy. Curr Opin Lipidol 2001;12:371-375.
15. Grady D, Herrington D, Bitter V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Follow-up HERS II. JAMA 2002;288:49-57.
16. Byington RP, Furberg CD, Riley W, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with documented heart disease: HERS B-mode substudy [abstract]. J Am Coll Cardiol 1999;33:(suppl 265A); No. 831-5.
17. Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: A randomized, controlled trial. J Am Coll Cardiol 2000;36:1789-1796.
18. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement therapy on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-529.
19. Angerer P, Stork S, Kothny W, et al. Postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-268.
20. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
21. Angerer P, Stork S, Kothny W, von Schacky C. Effect of postmenopausal hormone replacement therapy on atherosclerosis in femoral arteries. Maturitas 2002;41:51-60.
22. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 2001;104:2256-2259.
23. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE randomized trial. JAMA 2002;287:847-857.
24. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, et al. Applicability of cholesterol-lowering primary prevention trials to a general population: The Framingham Heart Study. Arch Intern Med 2001;161:949-954.
25. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
26. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69C-77C.
27. Westerveld HT, van Lennep JE, van Lennep HW, et al. Apolipoprotein B and coronary artery disease in women: A cross-sectional study in women undergoing their first angiography. Arterioscler Thromb Vasc Biol 1998;18:1101-1107.
28. Superko HR. Lipid disorders contributing to coronary heart disease: An update. Curr Probl Cardiol 1996;21:736-780.
29. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001;358:2026-2033.
30. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996:94:273-278.
31. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the AFCAPS/TexCAPS. Circulation 2000;101:477-484.
32. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160:3315-3325.
33. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogen and medroxyprogesterone acetate on plasma lipids, lipoproteins, coagulation factors and carbohydrate metabolism. Fertil Steril 2001;76:13-24.
34. Wakatsuki A, Ikenoue N, Sagara Y. Effect of estrogen on the size of low-density lipoprotein particles in postmenopausal women. Obstet Gynecol 1997;90:22-25.
35. Wakatsuki A, Ikenoue N, Okatani Y, Fukaya T. Estrogen-induced small low-density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 2001;37:425-430.
36. Brites FD, Bonavita CD, De Geitere C, et al. Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-C levels. Atherosclerosis 2000;152:181-192.
37. Carr MC, Ayyobi AF, Murdoch SJ, et al. Contribution of hepatic lipase, lipoprotein lipase, and cholesterol ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol 2002;22:667-673.
38. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.
39. Estradiol/Norgestimate (Ortho-Prefest) Product Information Sheet. 2002 Physicians Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company; 2002.
40. Maki KC, Davidson MH, Marx P, et al. Low density lipoprotein subclass distribution pattern does not modify serum lipid and apolipoprotein responses to hormone replacement therapy. October 1999 Proceedings. 9th International Menopause Society World Congress on the Menopause.
41. Hermenegildo C, Garcia-Martinez MC, Valldecabres C, et al. Transdermal estradiol reduces plasma myeloperoxidase levels without affecting the LDL resistance to oxidation or the LDL particle size. Menopause 2002;9:102-109.
42. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): A randomized controlled trial. JAMA 1996;276:1397-1403.
43. Estradiol/Norethindrone Acetate Transdermal System CombiPatch) Product Information Sheet. 2002 Physicians Desk Reference. 56th ed. Montvale, NJ: Medical Economics Company; 2002.
44. Davidson MH. Utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. Am J Cardiol 2001;87(4A):1A-7A.